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Rare De Novo Germline Copy-Number Variation in Testicular Cancer
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Although heritable factors are an important determinant of risk of early-onset cancer, themajority of these malignancies appear to occur
sporadically without identifiable risk factors. Germline de novo copy-number variations (CNVs) have been observed in sporadic neuro-
cognitive and cardiovascular disorders. We explored this mechanism in 382 genomes of 116 early-onset cancer case-parent trios and
unaffected siblings. Unique de novo germline CNVs were not observed in 107 breast or colon cancer trios or controls but were indeed
found in 7% of 43 testicular germ cell tumor trios; this percentage exceeds background CNV rates and suggests a rare de novo genetic
paradigm for susceptibility to some human malignancies.Heritability is an important determinant of cancer risk;
however, even in early-onset human cancers, the vast
majority of cases occur without identifiable hereditary or
other known risk factors. The role of de novo germline
copy-number variations (CNVs) in cancer susceptibility is
largely unknown, although de novo mutations in cancer-
susceptibility genes (e.g., APC [MIM 611731], RET [MIM
164761], RB1 [MIM 614041], and MEN1 [MIM 613733])
are common. Genomic assessment, especially of de novo
germline CNVs in disease-affected individuals, has defined
mechanisms of susceptibility for neurodevelopmental and
psychiatric disorders, as well as for congenital heart
disease. Studies of autism (MIM 209850), schizophrenia
(MIM 181500), intellectual disability, and tetralogy of
Fallot (TOF [MIM 187500]) have identified a higher inci-
dence of de novo CNVs in disease-affected children than
in controls.1–5 In this study, we explore the role of de
novo germline CNVs in early-onset sporadic (nonheredi-
tary) cancers and focus on individuals with early-onset
testicular germ cell tumors (TGCTs [MIM 273300]).
TGCTs are the most common solid malignancy in young
adult males, and the majority of TGCTs occur between
the ages of 15 and 35 years. Most TGCTs are sporadic,
but 2% of cases are familial.6 Family history of disease is
among the strongest risk factors for TGCTs: there is an
8- to 10-fold increase in risk for brothers of a TGCT index
case and a 4- to 6-fold increase in risk for fathers and
sons of a TGCT case.6 A 1.6 Mb deletion on the long arm
of the Y chromosome (i.e., the ‘‘gr/gr’’ deletion in the three
azoospermia factor [AZF] regions) has been associated
with a 2- to 3-fold increase in TGCT risk.7 Two TGCT
genome-wide association studies have identified common
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The Americ184745) and associated with a 2.55- to 3-fold increase in
TGCT risk.8,9 Although these low- to moderate-penetrance
susceptibility loci most likely contribute to disease risk, the
majority of early-onset TGCTs remain unexplained.
In this study, we ascertained DNA samples from case-
parent ‘‘trios’’ composed of a proband with a TGCT (diag-
nosed at or before 35 years of age), BRCA1/2 (MIM
113705 and MIM 600185)-mutation-negative breast
cancer (MIM 114480) (diagnosed at or before 45 years
of age), or early-onset colorectal cancer (CRC [MIM
114500]) (diagnosed at or before the age of 50) and the
two unaffected biologic parents of the cases. For additional
controls, DNA from unaffected offspring (siblings of cases)
was ascertained. Cases with multiple known cancer-
affected family members or a known predisposition to
cancer were excluded. The research protocol was approved
by the institutional review board at the Memorial Sloan-
Kettering Cancer Center, and written informed consent
was obtained from all subjects. DNA was obtained from
saliva and peripheral-blood lymphocytes for purposes
of confirmation. Analysis of CNVs was performed by
comparative genomic hybridization with the use of the
NimbleGen HD2 2.1 million probe microarray platform
(oligonucleotides were optimized for hybridization perfor-
mance, and uniform genome coverage provided a resolu-
tion to approximately 25 kb).4 DNA samples were analyzed
in NimbleGen’s Icelandic facility, where two-color hybrid-
izations with a single male reference genome were per-
formed. Complete experimental procedures are detailed
elsewhere.4,10,11 For system noise correction, we used local
and Lowess normalization and also performed self-self
hybridizations by using multiple reference genomes. On
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T68 NSGCT mixed germ cell tumor containing
yolk sac tumor and teratoma
IIIc 27 years 7q11.22 amplification 119 kb AUTS2
T74 NSGCT mixed germ cell tumor predominantly
containing embryonal cell carcinoma
and focus of immature teratoma
and seminoma
I 27 years 6p21.2 deletion 400 kb KIF6, KNCK16,
and KNCK17
T82 NSGCT mixed germ cell tumor containing
seminoma, embryonal carcinoma,
and yolk sac tumor
IIa 23 years 12q24.11 amplification 178 kb SSH1
The following abbreviation is used: NSGCT, nonseminomatous germ cell tumor.data, the principal components of system noise were deter-
mined and the distortion of genetic signal was mini-
mized.11 We used Kolmogorov-Smirnov (KS) segmenta-
tion, minimizing variance to segment the data, and KS
statistics to judge the significance of the segments.4 For
a given KS segmentation, states were only computed for
probes that passed a series of filters, including exclusion
of probes with more than two mappings and those that
occurred above a population threshold on the basis of
the frequency of polymorphisms over a set of 1,500
high-quality control hybridizations. Once the perfor-
mance parameters for each hybridization were character-
ized, the probability that a probe was a ‘‘Mendel violator’’
was calculated with a strict threshold for the Mendel viola-
tion p value of 109; this was the same stringent protocol
used in our recent study of nearly 1,000 autism case-parent
trios and controls.4 For comparison of the de novo events
between cases and controls, a two-tailed Fisher’s exact test
was applied. We used the two-sided binomial test to deter-
mine significant deviations of the observed number of
CNVs from a theoretically expected distribution of obser-
vations.
The median age of the 43 testicular cancer cases was
29 years (range¼ 19–35 years) at diagnosis; ten individuals
had a seminoma, and 33 had a nonseminomatous TGCT.
The frequency of de novo CNVs was compared in 60
breast cancer case-parent trios (median age ¼ 35 years;
range ¼ 20–45 years), 34 unaffected siblings (median
age ¼ 37 years; range ¼ 21–57 years), and 13 trios with
early-onset colorectal cancer (median age ¼ 38 years;
range ¼ 25–50 years). We identified three de novo deletion
or amplification events in three different TGCT probands
(Table 1) but did not identify any de novo germline
events in the unaffected siblings or in any of the early-
onset breast or colorectal cancer trios. Overall, we analyzed
382 genomes for CNVs and found a de novo germline CNV
in 7% (3 out of 43) of TGCT index cases and in none of the
107 unaffected siblings or early-onset breast or colorectal
cancer trios (p ¼ 0.02). Compared to the 7% rate of
de novo CNVs observed for testicular cancer, as well as
for congenital heart disease and autism,4 the lack of de
novo CNVs in the breast cancer trios (n ¼ 60; p ¼ 0.02)380 The American Journal of Human Genetics 91, 379–383, August 1and the combined breast and colon cancer trios (n ¼ 73;
p¼ 0.01) is significantly different than what was expected.
In the TGCT trios, the de novo CNVs identified (one
deletion and two amplification events) were 119 kb,
178 kb, and 400 kb in size (Figure 1). In one developmen-
tally normal young man who was diagnosed with
metastatic nonseminomatous testicular cancer at age 27,
a 119 kb amplification was present in region 7q11.22
(Figure 1A). The 7q11 locus has been implicated by
cytogenetic and genomic analyses as an area of frequent
somatic amplification in testicular germ cell tumors.12,13
This region also lies near autism susceptibility candidate
2 (AUTS2), which codes for a highly conserved neuronal
nuclear protein that is developmentally regulated and
implicated in autism and intellectual disabilities but
that has not been studied in tumors.14,15 A large 400 kb
de novo CNV in 6p21.2 (Figure 1B) encompasses a kinesin
family member 6 (KIF6 [MIM 613919]), which has not yet
been implicated in carcinogenesis. Finally, a 178 kb
gain-of-copy-number event was observed in 12q24.11
(Figure 1C). This region encompasses the phosphatase
slingshot-1 (SSH1), which was previously implicated in
the cofilin pathway activation and which might play
a role in cancer cell motility and invasion.16
To validate the specific de novo amplifications and dele-
tions discovered from the HD2 array, we used a Taqman
CNV approach, which confirmed the presence of the
events in the probands of interest in both saliva- and
blood-derived DNA (Figure 2). Next, we used Taqman
assays to determine the frequency of each of these genomic
events in a larger ascertainment of 113 sporadic TGCT
cases; none of the deletions or amplifications was detected,
suggesting the rarity of these specific genomic events.
Utilizing an agnostic genomic scan of case-parent trios,
we demonstrate de novo germline CNVs as a mechanism
of human cancer susceptibility. In other human diseases
for which de novo germline CNVs have been implicated
(e.g. autism and congenital heart disease), similar rates
of de novo events were identified (7%–9%) and were
considerably higher than the expected background rates
of 1%–2% for such events.1,2,4,5 On the basis of 1,500
controls analyzed with the same array platform, the0, 2012
Figure 1. Representation of De Novo Events in Testicular Germ Cell Tumors
The three de novo events include (A) an amplification in 7q11.22, (B) a deletion in 6p21.2, and (C) a duplication in 12q24.11. In each
panel, the probe log-ratio values for the mother, father, and proband appear in red, green, and blue, respectively. The probability that
a probe ‘‘violates’’ Mendelian inheritance was calculated, and polarity was assigned to this probability depending on whether the probe
in the proband was detecting a duplication (positive) or a deletion (negative).implicated genomic regions were not in areas of frequent
copy-number polymorphisms and repeat events were not
identified in 113 sporadic TGCT cases, suggesting that
these genomic events appear to be rare. Given sample-
size limitations, replication of our study in an independent
set of TGCT trios would provide further confirmation of
our findings.
In contrast, no de novo CNVs were identified in a cohort
of early-onset sporadic breast or colorectal cancer case-
parent trios. The de novo mutation paradigm might be
important but less readily evident in early-onset human
diseases in which the natural history of the disease wouldThe Americnormally result in decreased fecundity. Currently curable
by surgery, radiation, and/or chemotherapy,17 TGCTs
were previously a fatal cancer affecting young men before
they were able to reproduce. This observation might
explain the absence of detection of germline events in
the relatively rare Mendelian TGCT pedigrees ascertained
to date. In addition, in sperm samples banked prior to
treatment and in samples obtained after treatment, many
TGCT individuals retain qualitative and/or quantitative
defects in spermatogenesis.17 We also speculate that the
paradigm of a de novo germline etiology of disease might
be less applicable to late-onset cancers and more relevantan Journal of Human Genetics 91, 379–383, August 10, 2012 381
Figure 2. Validation of De Novo Events in Testicular Germ Cell
Tumors
(A–C) Taqman CNV assays confirm the presence of the de novo
amplifications or deletions in the three TGCT trios. In trio 68,
both saliva and blood were obtained from the proband (P and P*
for saliva and blood, respectively) for confirmation of the amplifi-
cation. The amplification or the deletion is present in the proband
(P) and absent in the parents (M and F) and controls (C1–C4). Error
bars indicate the standard deviation of the copy number for the
replicates.to very early-onset cancers for which a purifying selection
is more likely to eliminate the heritable susceptibility
factors. These findings might act to limit the vertical trans-
mission and accumulation of de novo germline structural
aberrations causing susceptibility to this disease. If correct,
this might in part explain the seemingly lower frequency
of de novo events in adult-onset breast and colon cancer
cases.
The identification of the genetic basis of TGCTs, as well
as other cancers, will require additional analysis of de novo
mutational and structural genomic events with the use of
next-generation-sequencing technologies. However, the
findings reported here indicate that a case-parent trio
design for the identification of de novo mutations in
early-onset sporadic cases might represent a new paradigm
for discovering mechanisms of susceptibility to human
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